ProCE Banner Activity

Venetoclax + Low-Dose Cytarabine in Elderly Patients With Untreated AML

Slideset Download
Conference Coverage
Early-phase study suggests promise of venetoclax plus low-dose cytarabine in untreated elderly patients with acute myeloid leukemia.

Released: June 06, 2016

Expiration: June 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals